The global orthobiologics market size was estimated to be USD 7.78 billion in 2023 and is expected to reach at USD 15.25 billion by 2034 with a CAGR of 6.31% during the forecast period 2024-2034. Growing prevalence of various bone conditions including malignant & benign bone tumors, bone infections such as osteomyelitis, increased utilization of stem cell-based allografts in diverse orthopedic procedures, rising trend in the application of viscosupplements to postpone total knee replacement surgeries, surge in number of patients experiencing osteoarthritis, growing prevalence of orthopedic injuries, surge in the introduction of new products and rising approvals for orthobiologics products are some of the key factors boosting the market growth.
Rising approvals for orthobiologics products is predicted to boost the market growth during the forecast period. Orthobiologics and regenerative medicine typically comprise naturally occurring substances within the body, employed to expedite the healing process of injuries. These products find application in orthopedic procedures to enhance the recovery of fractured bones, injured muscles, ligaments, and tendons. For instance, in May 2023, Locate Bio, a United Kingdom-based orthobiologics firm, is delighted to report that the Food and Drug Administration (FDA) has awarded Breakthrough Device designation to LDGraft. This product is presently under development for the treatment of Anterior Lumbar Interbody Spinal Fusion (ALIF) at a single level, specifically from L3-S1, catering to patients diagnosed with degenerative disc disease.
By product, viscosupplements was the highest revenue-grossing segment in the global orthobiologics market in 2023 owing to the rising prevalence of knee osteoarthritis and degenerative arthritis, increasing geriatric population, and growing number of approvals for viscosupplements. Additionally, synthetic bone substitutes is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of synthetic bone grafts, a gradual transition among healthcare professionals from traditional bone grafts to their synthetic alternatives, and increasing introduction of new products. For instance, in March 2022, SeaSpine has introduced the NorthStar cervical facet fusion and Flash navigation lumbar facet fusion orthobiologic systems. These are designed to enhance a consistent procedural workflow while optimizing the fusion area through the inclusion of OsteoStrand DBM fibers within the facet joint.
By application, spinal fusion was the highest revenue-grossing segment in the global orthobiologics market in 2023 owing to the growing prevalence of spinal fusion surgeries, rising approval of new products for spinal fusion procedures, and surge in the introduction of innovative offerings. For instance, in January 2023, Orthofix Medical Inc., a well-established global company in the field of spine and orthopedics, has officially launched the Mariner Deformity Pedicle Screw System and successfully performed its initial patient cases. Additionally, reconstructive & fracture surgery is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of fracture cases and increase in the prevalence of osteoporosis.
By end-user, hospitals & ASCs was the highest revenue-grossing segment in the global orthobiologics market in 2023 owing to surge in number of patient admissions, rising orthopedic procedures conducted within hospitals, an expansion in the count of hospitals, and an upsurge in the introduction of innovative products. For instance, in January 2022, Bone Solutions Inc. has introduced Mg OSTEOINJECT, the inaugural injectable bone void filler in the United States that includes magnesium, a vital element for bone health and growth. This product has the potential to enhance bone repair and regeneration in cases of insufficiency and micro fractures. Additionally, specialty clinics is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for specialized care, increased number of specialty clinics aimed at efficiently managing & treating bone defects, rise in the prevalence of joint complications and spinal disorders.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising acceptance of biologics for injuries and disorders related to bones, a heightened introduction of synthetic products, increase in the number of patients experiencing bone injuries, surge in orthopedic surgeries, and growing number of innovative product launches. For instance, in February 2023, Induce Biologics USA Inc has unveiled the NMP Strip Bioimplant, utilizing their distinctive Natural Matrix Protein (NMP) approach. This innovative cancellous bone-graft solution aims to unlock and make bioavailable the growth factors naturally present in bone tissue. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing investment in research & development activities, surge in the introduction of new products, growing prevalence of bone diseases, heightened awareness about biologics used in orthopedic procedures, and rise in approvals by regulatory bodies. For instance, in June 2023, Anika Therapeutics, Inc. declared that the U.S. FDA has granted them another 510(k) clearance for its injectable bone substitute, Tactoset.
Rising approvals for orthobiologics products is predicted to boost the market growth during the forecast period. Orthobiologics and regenerative medicine typically comprise naturally occurring substances within the body, employed to expedite the healing process of injuries. These products find application in orthopedic procedures to enhance the recovery of fractured bones, injured muscles, ligaments, and tendons. For instance, in May 2023, Locate Bio, a United Kingdom-based orthobiologics firm, is delighted to report that the Food and Drug Administration (FDA) has awarded Breakthrough Device designation to LDGraft. This product is presently under development for the treatment of Anterior Lumbar Interbody Spinal Fusion (ALIF) at a single level, specifically from L3-S1, catering to patients diagnosed with degenerative disc disease.
By product, viscosupplements was the highest revenue-grossing segment in the global orthobiologics market in 2023 owing to the rising prevalence of knee osteoarthritis and degenerative arthritis, increasing geriatric population, and growing number of approvals for viscosupplements. Additionally, synthetic bone substitutes is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of synthetic bone grafts, a gradual transition among healthcare professionals from traditional bone grafts to their synthetic alternatives, and increasing introduction of new products. For instance, in March 2022, SeaSpine has introduced the NorthStar cervical facet fusion and Flash navigation lumbar facet fusion orthobiologic systems. These are designed to enhance a consistent procedural workflow while optimizing the fusion area through the inclusion of OsteoStrand DBM fibers within the facet joint.
By application, spinal fusion was the highest revenue-grossing segment in the global orthobiologics market in 2023 owing to the growing prevalence of spinal fusion surgeries, rising approval of new products for spinal fusion procedures, and surge in the introduction of innovative offerings. For instance, in January 2023, Orthofix Medical Inc., a well-established global company in the field of spine and orthopedics, has officially launched the Mariner Deformity Pedicle Screw System and successfully performed its initial patient cases. Additionally, reconstructive & fracture surgery is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of fracture cases and increase in the prevalence of osteoporosis.
By end-user, hospitals & ASCs was the highest revenue-grossing segment in the global orthobiologics market in 2023 owing to surge in number of patient admissions, rising orthopedic procedures conducted within hospitals, an expansion in the count of hospitals, and an upsurge in the introduction of innovative products. For instance, in January 2022, Bone Solutions Inc. has introduced Mg OSTEOINJECT, the inaugural injectable bone void filler in the United States that includes magnesium, a vital element for bone health and growth. This product has the potential to enhance bone repair and regeneration in cases of insufficiency and micro fractures. Additionally, specialty clinics is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for specialized care, increased number of specialty clinics aimed at efficiently managing & treating bone defects, rise in the prevalence of joint complications and spinal disorders.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising acceptance of biologics for injuries and disorders related to bones, a heightened introduction of synthetic products, increase in the number of patients experiencing bone injuries, surge in orthopedic surgeries, and growing number of innovative product launches. For instance, in February 2023, Induce Biologics USA Inc has unveiled the NMP Strip Bioimplant, utilizing their distinctive Natural Matrix Protein (NMP) approach. This innovative cancellous bone-graft solution aims to unlock and make bioavailable the growth factors naturally present in bone tissue. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing investment in research & development activities, surge in the introduction of new products, growing prevalence of bone diseases, heightened awareness about biologics used in orthopedic procedures, and rise in approvals by regulatory bodies. For instance, in June 2023, Anika Therapeutics, Inc. declared that the U.S. FDA has granted them another 510(k) clearance for its injectable bone substitute, Tactoset.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Orthobiologics Market Report 2023 - 2034
Orthobiologics Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Demineralized Bone Matrix (DBM)
- Synthetic Bone Substitutes
- Bone Growth Factors
- Cellular Allograft
- Viscosupplements
- Allografts
- Others
Orthobiologics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Maxillofacial & Dental
- Reconstructive & Fracture Surgery
- Spinal Fusion
- Soft Tissue Repair
- Others
Orthobiologics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Specialty Clinics
- Hospitals & Ambulatory Surgical Centers (ASCs)
- Others
Orthobiologics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Orthobiologics Market: Product Estimates & Trend Analysis
8. Orthobiologics Market: Application Estimates & Trend Analysis
9. Orthobiologics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Orthobiologics Market
12. Europe Orthobiologics Market
13. Asia Pacific Orthobiologics Market
14. Latin America Orthobiologics Market
15. MEA Orthobiologics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- DePuy Synthes (A Subsidiary of Johnson & Johnson)
- Terumo Corporation
- Sanofi
- NuVasive Inc.
- Stryker Corporation
- Medtronic PLC
- Arthrex Inc.
- Bone Support
- Seaspine Holdings Corporation
- Zimmer Biomet
- Globus Medical Inc.
- Integra Lifesciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 7.78 Billion |
| Forecasted Market Value ( USD | $ 15.25 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
